14 unchanged sentences
(Exhibit 10.1)
−Removed: Amended and Restated Employment Agreement, dated June 13, 2023, by and between the Registrant and Satyavrat Shukla
−Removed: (Exhibit 10.3)
−Removed: Interim Period Agreement, dated January 10, 2025, by and between the Registrant and Satyavrat Shukla
−Removed: (Exhibit 10.1)
−Removed: Retention Letter Agreement, dated November 13, 2024, by and between the Registrant and Satyavrat Shukla
−Removed: (Exhibit 10.12)
Separation Agreement, dated April 28, 2025, by and between the Registrant and Satyavrat Shukla
−Removed: Separation Agreement, dated July 30, 2024 by and between the Registrant and Kamal Hamed, M.D.
(Exhibit 10.5)
−Removed: Employment Agreement, dated January 1, 2020, by and between the Registrant and Timothy Keutzer
−Removed: (Exhibit 10.12)
−Removed: Retention Letter Agreement, dated November 13, 2024, by and between the Registrant and Timothy Keutzer
−Removed: (Exhibit 10.19)
−Removed: Employment Agreement, dated October 31, 2023 by and between the Registrant and Esther Rajavelu
−Removed: (Exhibit 10.1)
Amended and Restated Employment Agreement, dated April 28, 2025, by and between the Registrant and Esther Rajavelu
−Removed: Interim Period Agreement, dated January 10, 2025, by and between the Registrant and Esther Rajavelu
(Exhibit 10.5)
−Removed: Retention Letter Agreement, dated November 13, 2024, by and between the Registrant and Esther Rajavelu
−Removed: (Exhibit 10.22)
−Removed: Consulting Agreement, effective as of August 5, 2024, by and between the Registrant and John C.
−Removed: Pottage, Jr., M.D.
−Removed: (Exhibit 10.3)
−Removed: Amended and Restated Consulting Agreement, effective as of January 29, 2025, by and between the Registrant and John C.
−Removed: Pottage, Jr., M.D.
−Removed: (Exhibit 10.28)
−Removed: Amendment 3 to Exclusive License Agreement, dated March 4, 2024, by and between the Registrant and GlaxoSmithKline Intellectual Property (No.
−Removed: (Exhibit 10.4)
−Removed: Amendment 4 to Exclusive License Agreement, dated October 28, 2024, by and between the Registrant and GlaxoSmithKline Intellectual Property (No.
−Removed: (Exhibit 10.4)
−Removed: Spero Therapeutics, Inc.
−Removed: Insider Trading Policy, effective as of June 5, 2023
−Removed: (Exhibit 19.1)
Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
8 unchanged sentences
Cover Page Interactive Data File (embedded within the Inline XBRL document)
−Removed: # Management contract or compensatory plan.
−Removed: Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (“[***]”) because the identified confidential portions (i) are not material and (ii) is the type that the Registrant treats as private or confidential.
* The certification attached as Exhibit 32 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Spero Therapeutics, Inc.
2 unchanged sentences
SPERO THERAPEUTICS, INC.
+Added: August 12, 2025
/s/ Esther Rajavelu
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.